Trillium Asset Management, LLC Alkermes Plc. Transaction History

Trillium Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 06, 2019	SELL	$28.4 - $36.49 $363,406 - $466,926	-12,796 Closed	0 $0
Q4 2018 Feb 08, 2019	SELL	$27.94 - $44.61 $3,017 - $4,817	-108 Reduced 0.84%	12,796 $378,000
Q3 2018 Nov 09, 2018	BUY	$38.6 - $46.12 $7,411 - $8,855	192 Added 1.51%	12,904 $548,000
Q2 2018 Aug 01, 2018	BUY	$40.56 - $51.36 $9,450 - $11,966	233 Added 1.87%	12,712 $523,000
Q1 2018 May 09, 2018	SELL	$53.61 - $67.26 $292,656 - $367,172	-5,459 Reduced 30.43%	12,479 $723,000
Q4 2017 Feb 01, 2018	SELL	$47.69 - $55.39 $1.46 Million - $1.69 Million	-30,581 Reduced 63.03%	17,938 $982,000
Q3 2017 Nov 02, 2017	BUY	$49.16 - $54.45 $2.39 Million - $2.64 Million	48,519	48,519 $2.47 Million

363

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.67B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Trillium Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Trillium Asset Management, LLC with notifications on news.